A Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) CEP of the European Pharmacopoeia monograph is often referred to as a Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) Certificate of Suitability (COS). The purpose of a Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) to their clients by showing that a Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) CEP has been issued for it. The manufacturer submits a Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) CEP (COS) as part of the market authorization procedure, and it takes on the role of a Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) CEP holder for the record. Additionally, the data presented in the Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) DMF.
A Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) suppliers with CEP (COS) on PharmaCompass.